The future of pharmacogenetics in the treatment of migraine

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Headache Classification of the International Headache Society. The international classification of headache disorders, 3rd edition (beta version). Cephalalgia 33, 627–808 (2013).
  MedlineGoogle Scholar
• 2. Lanteri-Minet M . Economic burden and costs of chronic migraine. Curr. Pain headache Rep. 18(1), 385 (2014).
  MedlineGoogle Scholar
• 3. GBD 2016 Headache Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 390(2017), 1211–1259 (2017).
  MedlineGoogle Scholar
• 4. Steiner TJ , Stovner LJ , Vos T et al. Migraine is first cause of disability in under 50s: will health politicians now take notice? J. Headache Pain 19, 17 (2018).
  MedlineGoogle Scholar
• 5. Steiner TJ , Birbeck GL , Jensen RH et al. Headache disorders are third cause of disability worldwide. J. Headache Pain 16, 58 (2015).
  MedlineGoogle Scholar
• 6. Martelletti p , Giamberardino MA . Advances in orally administered pharmacotherapy for the treatment of migraine. Exp. Opin. Pharmacother. 20(2), 209–218 (2019).
  Medline CASGoogle Scholar
• 7. Weatherall MW . The diagnosis and treatment of chronic migraine. Ther. Adv. Chronic Dis. 6, 115–123 (2015).
  Medline CASGoogle Scholar
• 8. Affaitati G , Martelletti P , Lopopolo M et al. Use of nonsteroidal anti-inflammatory drugs for symptomatic treatment of episodic headache. Pain Pract. 17(3), 392–401 (2017).
  MedlineGoogle Scholar
• 9. Belvis R , Mas N , Aceituno A . Migraine attack treatment: a tailormade suit, not one size fits all. Recent Pat. CNS Drug Discov. 9(1), 26–40 (2014).
  Medline CASGoogle Scholar
• 10. Giamberardino MA , Martelletti P . Emerging drugs for migraine treatment. Exp. Opin. Emerg. Drugs 20(1), 137–147 (2015).
  Medline CASGoogle Scholar
• 11. Marmura MJ , Silberstein SD , Schwedt TJ . The acute treatment of migraine in adults: the american headache society evidence assessment of migraine pharmacotherapies. Headache 55(1), 3–20 (2015).
  MedlineGoogle Scholar
• 12. Vongvaivanich K , Lertakyamanee P , Silberstein SD et al. Late-life migraine accompaniments: a narrative review. Cephalalgia 35, 894–911 (2015).
  MedlineGoogle Scholar
• 13. van Os HJA , Mulder IA , Broersen A et al. Migraine and cerebrovascular atherosclerosis in patients with ischemic stroke. Stroke 48, 1973–1975 (2017).
  MedlineGoogle Scholar
• 14. Seidel S , Beisteiner R , Manecke M et al. Psychiatric comorbidities and photophobia in patients with migraine. J. Headache Pain 18, 18 (2017).
  MedlineGoogle Scholar
• 15. Rainero I , Govone F , Gai A et al. Is migraine primarily a metaboloendocrine disorder? Curr. Pain Headache Rep. 22, 36 (2018).
  MedlineGoogle Scholar
• 16. de Tommaso M , Sciruicchio V , Delussi M et al. Symptoms of central sensitization and comorbidity for juvenile fibromyalgia in childhood migraine: an observational study in a tertiary headache center. J. Headache Pain 18, 59 (2017).
  MedlineGoogle Scholar
• 17. Ferrari A , Baraldi C , Licata M et al. Polypharmacy among headache patients: a cross-sectional study. CNS Drugs 32, 1 (2018).
  MedlineGoogle Scholar
• 18. Gentile G , Cipolla F , Capi M , Simmaco M , Lionetto L , Borro M . Precise medical decision making in geriatric anti-depressant therapy. Exp. Rev. Precision Med. Drug Dev. 1(4), 387–396 (2016).
  Google Scholar
• 19. Gasparini CF , Sutherland HG , Griffiths LR . Studies on the pathophysiology and genetic basis of migraine. Curr. Genomics 14, 300–315 (2013).
  Medline CASGoogle Scholar
• 20. Schurks M . Genetics of migraine in the age of genome-wide associations studies. J. Headache Pain 13(1), 1–9 (2012).
  MedlineGoogle Scholar
• 21. Zorina-Lichtenwalter K , Meloto CB , Khoury S et al. Genetic predictions of human chronic pain conditions. Neuroscience 338, 36–62 (2016).
  Medline CASGoogle Scholar
• 22. Gentile G , Borro M , Noemi L et al. Genetic polymorphism related to efficacy and overuse of triptans in chronic migraine. J. Headache Pain 11, 431–435 (2010).
  Medline CASGoogle Scholar
• 23. Gentile G , Borro M , Simmaco M et al. Gene polymorphisms involved in triptans pharmacokinetics and pharmacodynamics in migraine therapy. Exp. Opin. Drug Metab. Toxicol. 7(1), 39–47 (2011).
  Medline CASGoogle Scholar
• 24. Piane M , Lulli P , Farinelli I et al. Genetics of migraine and pharmacogenomics: some considerations. J. Headache Pain 8, 334–339 (2007).
  Medline CASGoogle Scholar
• 25. Collins FS . Genetics: an explosion of knowledge is transforming clinical practice. Geriatrics 54, 41–47 (1999).
  Medline CASGoogle Scholar
• 26. Weinshilboum R . Inheritance and drug response. N. Engl. J. Med. 348, 529–537 (2003).
  MedlineGoogle Scholar
• 27. Simmaco M , Borro M , Missori S et al. Pharmacogenomics in migraine: catching biomarkers for a predictable disease control. Exp. Rev. Neurother. 9(9), 1267–1269 (2009).
  MedlineGoogle Scholar
• 28. Belvis R , Mas N , Aceituno A . Migraine attack treatment: a tailormade suit, not one size fits all. Recent Pat. CNS Drug Discov. 9(1), 26–40 (2014).
  Medline CASGoogle Scholar
• 29. Holland PR , Goadsby PJ . Targeted CGRP small molecule antagonists for acute migraine therapy. Neurotherapeutics 15(2), 304–312 (2018).
  Medline CASGoogle Scholar
• 30. Gentile G , Chiossi L , Lionetto L et al. Pharmacogenetic insights into migraine treatment in children. Pharmacogenomics 15(11), 1539–1550 (2014). •• Exhaustive review of the management of pediatric migraine.
  CASGoogle Scholar
• 31. González-Hernández A , Marichal-Cancino B , MaassenVanDenBrink A et al. Side effects associated with current and prospective antimigraine pharmacotherapies. Exp. Opin. Drug Metab. Toxicol. 14(1), 25–41 (2018).
  Medline CASGoogle Scholar
• 32. Zanger UM , Schwab M . Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol. Ther. 138, 103–141 (2013).
  Medline CASGoogle Scholar
• 33. Samer CF , Lorenzini KI , Rollason V et al. Applications of CYP450 testing in the clinical setting. Mol. Diagn. Ther. 17(3), 165–184 (2013).
  Medline CASGoogle Scholar
• 34. Division of Clinical Pharmacology at Indiana University School of Medicine. Cytochrome P450 drug interactions table (2016). www.thblack.com/links/RSD/8_drug_interactions_table.pdf
  Google Scholar
• 35. Division of Clinical Pharmacology at Indiana University School of Medicine. P450 drug interaction table (2016). http://medicine.iupui.edu/clinpharm/ddis/main-table/
  Google Scholar
• 36. Madhusoodanan S , Velama U , Parmar J et al. A current review of cytochrome P450 interactions of psychotropic drugs. Ann. Clin. Psychiatry 26, 120–138 (2014).
  MedlineGoogle Scholar
• 37. Palleria C , Di Paolo A , Giofrè C et al. Pharmacokinetic drug–drug interaction and their implication in clinical management. J. Res. Med. Sci. 18, 601–610 (2013).
  MedlineGoogle Scholar
• 38. Lionetto L , Borro M , Curto M et al. Choosing the safest acute therapy during chronic migraine prophylactic treatment: pharmacokinetic and pharmacodynamic considerations. Exp. Opin. Drug Metab. Toxicol. 12(4), 399–406 (2016). •• Important review for drug–drug interactions (DDIs) in migraine polytherapy.
  Medline CASGoogle Scholar
• 39. Medscape. Drug interaction checker. http://reference.medscape.com/drug-interactionchecker. • Helpful tool for checking DDIs.
  Google Scholar
• 40. Drug interactions checker. www.drugs.com/drug_interactions.html • Helpful tool for checking DDIs.
  Google Scholar
• 41. University of Liverpool. Drug interaction checker. www.hep-druginteractions.org/checker • Helpful tool for checking DDIs.
  Google Scholar
• 42. Montagna P , Pierangeli G , Cevoli S et al. Pharmacogenetics of headache treatment. Neurol Sci. 26(Suppl. 2), S143–S147 (2005).
  MedlineGoogle Scholar
• 43. Tfelt-Hansen P , Brøsen K . Pharmacogenomics and migraine: possible implications. J. Headache Pain 9(1), 13–18 (2008).
  MedlineGoogle Scholar
• 44. Borro M , Gentile G , Cipolloni L et al. Personalised healthcare: the DiMA clinical model. Curr. Pharm. Biotechnol. 18, 242–252 (2017).
  Medline CASGoogle Scholar
• 45. Pomes LM , Gentile G , Simmaco M et al. Tailoring treatment in polymorbid migraine patients through personalized medicine. CNS Drugs 32(6), 559–565 (2018). •• An intriguing personalized medicine strategy for tailored prescription of migraine polytherapy.
  MedlineGoogle Scholar
• 46. Ong JJY , De Felice M . Migraine treatment: current acute medications and their potential mechanisms of action. Neurotherapeutics 15(2), 274–290 (2018).
  Medline CASGoogle Scholar
• 47. Andersson PG , Jespersen LT . Dihydroergotamine nasal spray in the treatment of attacks of cluster headaches. Cephalalgia 6, 51–54 (1986).
  Medline CASGoogle Scholar
• 48. Kirthi V , Derry S , Moore RA et al. Aspirin with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst. Rev. 4, CD008041 (2010).
  Google Scholar
• 49. Rabbie R , Derry S , Moore RA et al. Ibuprofen with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst. Rev. 10, CD008039 (2010).
  Google Scholar
• 50. Derry S , Moore RA , McQuay HJ . Paracetamol (acetaminophen) with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst. Rev. 11, CD008040 (2010).
  Google Scholar
• 51. Sostres C , Gargallo CJ , Arroyo MT et al. Adverse effects of nonsteroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract. Best Pract. Res. Clin. Gastroenterol. 24(2), 121–132 (2010).
  Medline CASGoogle Scholar
• 52. Wolfe MM , Lichtenstein DR , Singh GN . Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. Engl. J. Med. 340(24), 1888–1899 (1999).
  Medline CASGoogle Scholar
• 53. Fowler TO , Durham CO , Planton J et al. Use of nonsteroidal anti-inflammatory drugs in the older adult. J. Am. Assoc. Nurse Pract. 26(8), 414–423 (2014).
  MedlineGoogle Scholar
• 54. Papetti L , Spalice A , Nicita F et al. Migraine treatment in developmental age: guidelines update. J. Headache Pain 11(3), 267–276 (2010).
  MedlineGoogle Scholar
• 55. Kuehl GE , Bigler J , Potter JD et al. Glucuronidation of the aspirin metabolite salicylic acid by expressed UDP-glucuronosyltransferases and human liver microsomes. Drug Metab. Dispos. 34(2), 199–202 (2006).
  Medline CASGoogle Scholar
• 56. García-Martín E , Martínez C , Tabarés B et al. Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms. Clin. Pharmacol. Ther. 76(2), 119–127 (2004).
  Medline CASGoogle Scholar
• 57. Rollason V , Samer CF , Daali Y et al. Prediction by pharmacogenetics of safety and efficacy of non-steroidal anti- inflammatory drugs: a review. Curr. Drug Metab. 15(3), 326–343 (2014).
  Medline CASGoogle Scholar
• 58. Anzai N , Kanai Y , Endou H . Organic anion transporter family: current knowledge. J. Pharmacol. Sci. 100(5), 411–426 (2006).
  Medline CASGoogle Scholar
• 59. Theken KN . Variability in analgesic response to non-steroidal anti-inflammatory drugs. Prostaglandins Other Lipid Mediat. 139, 63–70 (2018).
  Medline CASGoogle Scholar
• 60. Andersen V , Vogel U . Systematic review: interactions between aspirin, and other nonsteroidal anti-inflammatory drugs, and polymorphisms in relation to colorectal cancer. Aliment. Pharmacol. Ther. 40(2), 147–159 (2014).
  Medline CASGoogle Scholar
• 61. Makar KW , Poole EM , Resler AJ et al. COX-1 (PTGS1) and COX-2 (PTGS2) polymorphisms, NSAID interactions, and risk of colon and rectal cancers in two independent populations. Cancer Causes Control 24(12), 2059–2075 (2013).
  MedlineGoogle Scholar
• 62. Marjan MN , Hamzeh MT , Rahman E et al. A computational prospect to aspirin side effects: aspirin and COX-1 interaction analysis based on non-synonymous SNPs. Comput. Biol. Chem. 51, 57–62 (2014).
  Medline CASGoogle Scholar
• 63. Perkins JR , Acosta-Herrera M , Plaza-Serón MC et al. Polymorphisms in CEP68 gene associated with risk of immediate selective reactions to non-steroidal anti-inflammatory drugs. Pharmacogenomics J. 19(2), 191–199 (2019).
  Medline CASGoogle Scholar
• 64. Jóźwiak-Bebenista M , Nowak JZ . Paracetamol: mechanism of action, applications and safety concern. Acta Pol. Pharm. 71(1), 11–23 (2014).
  Medline CASGoogle Scholar
• 65. Mazaleuskaya LL , Sangkuhl K , Thorn CF et al. PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet. Genomics 25(8), 416–426 (2015).
  Medline CASGoogle Scholar
• 66. Navarro SL , Chen Y , Li L et al. UGT1A6 and UGT2B15 polymorphisms and acetaminophen conjugation in response to a randomized, controlled diet of select fruits and vegetables. Drug Metab. Dispos. 39(9), 1650–1657 (2011).
  Medline CASGoogle Scholar
• 67. Court MH , Freytsis M , Wang X et al. The UDP-glucuronosyltransferase (UGT) 1A polymorphism c.2042C>G (rs8330) is associated with increased human liver acetaminophen glucuronidation, increased UGT1A exon 5a/5b splice variant mRNA ratio, and decreased risk of unintentional acetaminophen-induced acute liver failure. J. Pharmacol. Exp. Ther. 345(2), 297–307 (2013).
  Medline CASGoogle Scholar
• 68. Court MH , Peter I , Hazarika S et al. Candidate gene polymorphisms in patients with acetaminophen-induced acute liver failure. Drug Metab. Dispos. 42(1), 28–32 (2014).
  Medline CASGoogle Scholar
• 69. Ueshima Y , Tsutsumi M , Takase S et al. Acetaminophen metabolism in patients with different cytochrome P-4502E1 genotypes. Alcohol. Clin. Exp. Res. 20(Suppl. 1), 25A–28A (1996).
  Medline CASGoogle Scholar
• 70. Kang SH , Jung YH , Kim HY et al. Effect of paracetamol use on the modification of the development of asthma by reactive oxygen species genes. Ann. Allergy Asthma Immunol. 110(5), 364–369 (2013).
  Medline CASGoogle Scholar
• 71. Macone AE , Perloff MD . Triptans and migraine: advances in use, administration, formulation, and development. Exp. Opinion Pharmacother. 18(4), 387–397 (2017).
  Medline CASGoogle Scholar
• 72. Ferrari A , Sternieri E , Ferraris E et al. Emerging problems in the pharmacology of migraine: interactions between triptans and drugs for prophylaxis. Pharmacol. Res. 48(1), 1–9 (2003).
  Medline CASGoogle Scholar
• 73. Terrazzino S , Viana M , Floriddia E et al. The serotonin transporter gene polymorphism STin2 VNTR confers an increased risk of inconsistent response to triptans in migraine patients. Eur. J. Pharmacol. 641(2–3), 82–87 (2010).
  Medline CASGoogle Scholar
• 74. Tzvetkov MV . OCT1 pharmacogenetics in pain management: is a clinical application within reach? Pharmacogenomics 18(16), 1515–1523 (2017).
  CASGoogle Scholar
• 75. Cargnin S , Viana M , Sances G et al. Using a genetic risk score approach to predict headache response to triptans in migraine without aura. J. Clin. Pharmacol. 59(2), 288–294 (2019).
  Medline CASGoogle Scholar
• 76. Dusitanond P , Young WB . Neuroleptics and migraine. Cent. Nerv. Syst. Agents Med. Chem. 9(1), 63–70 (2009).
  Medline CASGoogle Scholar
• 77. Ravyn D , Ravyn V , Lowney R et al. CYP450 pharmacogenetic treatment strategies for antipsychotics: a review of the evidence. Schizophr. Res. 149(1–3), 1–14 (2013).
  MedlineGoogle Scholar
• 78. Charbit AR , Akerman S , Goadsby PJ . Dopamine: what's new in migraine? Curr. Opin. Neurol. 23(3), 275–281 (2010).
  Medline CASGoogle Scholar
• 79. Dresser GK , Spence JD , Bailey DG . Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin. Pharmacokinet. 38(1), 41–57 (2000).
  Medline CASGoogle Scholar
• 80. Kellerman D , Kori S , Forst A et al. Lack of drug interaction between the migraine drug MAP0004 (orally inhaled dihydroergotamine) and a CYP3A4 inhibitor in humans. Cephalalgia 32(2), 150–158 (2012).
  Medline CASGoogle Scholar
• 81. Antonaci F , Ghiotto N , Wu S et al. Recent advances in migraine therapy. Springerplus 5, 637 (2016).
  MedlineGoogle Scholar
• 82. Sprenger T , Viana M , Tassorelli C . Current prophylactic medications for migraine and their potential mechanisms of action. Neurotherapeutics 15(2), 313–323 (2018).
  Medline CASGoogle Scholar
• 83. Ye Q , Yan LY , Xue LJ et al. Flunarizine blocks voltage-gated Na⁽⁺⁾ and Ca⁽²⁺⁾ currents in cultured rat cortical neurons: a possible locus of action in the prevention of migraine. Neurosci. Lett. 487(3), 394–399 (2011).
  Medline CASGoogle Scholar
• 84. Ye Q , Wang Q , Yan LY et al. Flunarizine inhibits sensory neuron excitability by blocking voltage-gated Na⁺ and Ca²⁺ currents in trigeminal ganglion neurons. Chin. Med. J. 124(17), 2649–2655 (2011).
  Medline CASGoogle Scholar
• 85. Park JJ , Park KW , Kang J et al. CYP3A4 genetic status may be associated with increased vulnerability to the inhibitory effect of calcium-channel blockers on clopidogrel. Circ. J. 77(5), 1289–1296 (2013).
  Medline CASGoogle Scholar
• 86. Höcht C , Mayer MA , Opezzo JAW et al. Pharmacokinetic pharmacodynamic modeling of antihypertensive drugs: from basic research to clinical practice. Curr. Hypertens. Rev. 4, 289–302 (2008).
  CASGoogle Scholar
• 87. Li S , Lin H , Sun W et al. A meta-analysis of the effect of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamics of metoprolol. Int. J. Clin. Pharmacol. Ther. 55, 483–492 (2017). •• Describes comprehensively the pharmacokinetic and pharmacodynamic factors contributing to variability in the response to antihypertensive drugs.
  MedlineGoogle Scholar
• 88. Vandell AG , Lobmeyer MT , Gawronski BE et al. G protein receptor kinase 4 polymorphisms: β-blocker pharmacogenetics and treatment-related outcomes in hypertension. Hypertension 60(4), 957–964 (2012).
  Medline CASGoogle Scholar
• 89. He F , Luo J , Luo Z , Fan L et al. The KCNH2 genetic polymorphism (1956, C>T) is a novel biomarker that is associated with CCB and α,β-ADR blocker response in EH patients in China. PLoS ONE 8(4), e61317 (2013).
  Medline CASGoogle Scholar
• 90. Huang J , Li C , Song Y et al. ADRB2 polymorphism Arg16Gly modifies the natural outcome of heart failure and dictates therapeutic response to β-blockers in patients with heart failure. Cell Discov. 4, 57 (2018).
  MedlineGoogle Scholar
• 91. Cavallari LH , Mason DL . Cardiovascular pharmacogenomics – implications for patients with CKD. Adv. Chronic Kidney Dis. 23(2), 82–90 (2016).
  MedlineGoogle Scholar
• 92. Shahin MH , Conrado DJ , Gonzalez D . Genome-wide association approach identified novel genetic predictors of heart rate response to β-blockers. J. Am. Heart Assoc. 7(5), pii:e006463 (2018).
  Google Scholar
• 93. Niu Y , Gong Y , Langaee TY et al. Genetic variation in the beta2 subunit of the voltage-gated calcium channel and pharmacogenetic association with adverse cardiovascular outcomes in the INternational VErapamil SR-Trandolapril STudy GENEtic Substudy (INVEST-GENES). Circ. Cardiovasc. Genet. 3(6), 548–555 (2010).
  Medline CASGoogle Scholar
• 94. Tchivileva IE , Lim PF , Smith SB . Effect of catechol-O-methyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: a randomized, double-blind, placebo-controlled, crossover pilot study. Pharmacogenet. Genomics 20(4), 239–248 (2010).
  Medline CASGoogle Scholar
• 95. Burch R . Antidepressants for preventive treatment of migraine. Curr. Treat Options Neurol. 21(4), 18 (2019).
  MedlineGoogle Scholar
• 96. Steimer W , Zöpf K , von Amelunxen S et al. Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy. Clin. Chem. 51(2), 376–385 (2005).
  Medline CASGoogle Scholar
• 97. Roberts RL , Joyce PR , Mulder RT et al. A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression. Pharmacogenomics J. 2(3), 191–196 (2002).
  Medline CASGoogle Scholar
• 98. Capi M , Gentile G , Lionetto L et al. Pharmacogenetic considerations for migraine therapies. Expert Opin. Drug Metab. Toxicol. 14(11), 1161–1167 (2018).
  Medline CASGoogle Scholar
• 99. Curto M , Capi M , Martelletti P et al. How do you choose the appropriate migraine pharmacotherapy for an elderly person? Exp. Opinion Pharmacother. 20(1), 1–3 (2019).
  MedlineGoogle Scholar
• 100. Pomes LM , Guglielmetti M , Bertamino E . Optimising migraine treatment: from drug–drug interactions to personalized medicine. J.Headache Pain doi:10.1186/s10194-019-1010-3 (2019) (Epub ahead of print). •• An intriguing personalized medicine strategy for tailored prescription of migraine polytherapy.
  MedlineGoogle Scholar
• 101. Klein ME , Parvez MM , Shin JG . Clinical implementation of pharmacogenomics for personalized precision medicine: barriers and solutions. J. Pharm. Sci. 106(9), 2368–2379 (2017).
  Medline CASGoogle Scholar
• 102. Kelley EF , Snyder EM et al. Economic evaluation of a pharmacogenomic multi-gene panel test to optimize anti-hypertension therapy: simulation study. J. Med. Economics 21(12), 1246–1253 (2018).
  MedlineGoogle Scholar